FAQ on Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results and Rare Disease Pipeline Progress

What are the key highlights from Soligenix’s Q2 2025 results?

Key highlights include the expectation of top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, active enrollment in a confirmatory Phase 3 trial of HyBryte(TM) for early-stage CTCL with results anticipated in 2026, and completion of a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease.

What is HyBryte(TM) and what is its significance?

HyBryte(TM) (SGX301 or synthetic hypericin) is a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), representing a significant advancement in addressing an unmet medical need in rare diseases.

How did Soligenix perform financially in Q2 2025?

Soligenix reported a net loss of $2.7 million, or ($0.82) per share, with R&D expenses rising to $1.7 million due to higher trial and manufacturing costs, and cash reserves of $5.1 million as of June 30, 2025, plus an additional $1.4 million raised on July 1.

What are the upcoming milestones for Soligenix?

Upcoming milestones include the release of top-line Phase 2a results for SGX302 in psoriasis before year-end and the anticipated results of the confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL in 2026.

What is the significance of the Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease?

The study achieved its primary objective of demonstrating biological efficacy, marking a significant step forward in the development of a treatment for Behçet’s Disease, a rare and challenging condition.

How is Soligenix funding its operations?

Soligenix is funding its operations through its cash reserves, which stood at $5.1 million on June 30, 2025, plus $1.4 million raised on July 1, expected to fund operations into Q1 2026.

What is Soligenix’s focus in its Public Health Solutions business segment?

This segment focuses on developing vaccines for ricin toxin, filoviruses like Marburg and Ebola, and CiVax(TM) for COVID-19, utilizing its proprietary ThermoVax(R) heat stabilization platform technology, supported by government grants and contracts.

Where can I find more information about Soligenix?

More information can be found on the company’s website at www.Soligenix.com or in the company’s newsroom at https://ibn.fm/SNGX.